Next Article in Journal
Physical Activity and Physical Function One Year After Hospital Discharge for COVID-19
Previous Article in Journal
Harnessing Regenerative Science in Aesthetic Surgery: The Biologically Driven Future
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 17
10.3390/jcm14176203
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Clot Composition and Ischemic Stroke Etiology: A Contemporary Narrative Review

by
Jacob Kosyakovsky
1,
Christina P. Rossitto
1,
Joseph P. Antonios
2,
Daniela Renedo
2,
Christopher J. Stapleton
1,
Lauren H. Sansing
3,
Dhasakumar S. Navaratnam
3,
James A. Giles
3,
Aman B. Patel
1,
Charles C. Matouk
2,4,* and
Nanthiya Sujijantarat
2,*
1
Department of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA 02115, USA
2
Department of Neurosurgery, Yale-New Haven Hospital, Yale University, New Haven, CT 06510, USA
3
Department of Neurology, Yale-New Haven Hospital, Yale University, New Haven, CT 06510, USA
4
Department of Radiology, Yale-New Haven Hospital, Yale University, New Haven, CT 06510, USA
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(17), 6203; https://doi.org/10.3390/jcm14176203
Submission received: 17 July 2025 / Revised: 24 August 2025 / Accepted: 27 August 2025 / Published: 2 September 2025
(This article belongs to the Special Issue Current Advances and Future Perspectives of Ischemic Stroke)
Browse Figures
Versions Notes

Abstract

Acute ischemic stroke (AIS) is one of the leading global causes of mortality and morbidity. Clearer understanding of stroke etiology is a major clinical objective to determine appropriate strategies for secondary stroke prevention. Histological and molecular analysis of clots retrieved during mechanical thrombectomy (MT) in AIS offers a unique opportunity to study clot composition and its relation to stroke etiology. The field of clot composition analysis has undergone substantial growth in recent years, driven in part by the establishment of MT as the standard of care, as well as its expanding indications. Although many features differ between large-artery atherosclerosis (LAA) and cardioembolic (CE) clots, application of these findings to predicting stroke etiology at a clinical level remains challenging. Moreover, a significant number of patients have multiple comorbidities or suffer a cryptogenic subtype. Next-generation techniques such as multiomic sequencing offer a powerful potential to elevate our understanding of clot pathology and provide the level of granularity required for clinical diagnosis and management. Herein, we provide an updated review of the current state of the field by exploring stroke etiologies and their relationship to clot pathology, including classic histologic features as well as more recent, emerging results from proteomic and transcriptomic analyses.

1. Introduction

Acute ischemic stroke (AIS) is one of the leading causes of global mortality and morbidity [1,2]. Fibrinolysis with tissue plasminogen activator (tPA) or, most recently, tenecteplase (TNK) remains the first-line treatment for AIS patients meeting eligibility criteria [3,4]. The eligibility criteria include, but are not limited to, adult patients with presentation up to 3 or 4.5 h of onset, and absence of contraindications such as intracranial hemorrhage, recent surgery, or known coagulopathy [5]. Large-vessel occlusion (LVO) represents a subset of AIS cases whereby blockage occurs in a proximal vessel, and is estimated to be responsible for 7.2% of stroke code alerts [6], and 4.9% in patients with suspected stroke symptoms, by emergency medical technicians (EMTs) [7]. Over the past decade, the management of LVO has been transformed by widespread adoption of endovascular therapy with mechanical thrombectomy (MT) [8]. Beginning in 2015, a series of landmark trials established MT as the standard of care for patients with LVO presenting up to 8 h of last known well (LKW) [9,10,11,12,13]. Subsequent trials expanded the treatment window up to 24 h [14,15,16]. Today, patients meeting inclusion criteria are simultaneously triaged for both medical and endovascular intervention.
Beyond acute care, effective stroke management depends on accurate identification of etiology to guide secondary stroke prevention. The TOAST classification [17] provides a clinical framework to categorize stroke etiology and is detailed in Table 1. While cardioembolism (CE) represents a major identified cause [18], it is not uncommon for patients to have multiple comorbidities, as the risk factors for these conditions frequently overlap [18]. Additionally, cryptogenic strokes were estimated to be responsible for up to 30–40% of patients [19]. Because the risk of recurrent stroke is high, up to 30% within ten years [19], these scenarios can pose a major clinical challenge in secondary stroke prevention. The search for clinical or biological indicators of stroke etiology has been the focus of substantial research effort, given its direct implications for clinical management [20].
MT, especially with the popularization of direct aspiration techniques, has provided a unique opportunity to study clot pathology [21]. The retrieval of clots that would otherwise be inaccessible enables “endovascular biopsy” [22], which offers insights into the mechanisms responsible for these LVOs. This review aims to examine the most current literature exploring the relationship between clot composition and stroke etiology to date. We summarize key studies comparing large-artery atherosclerotic (LAA) and CE clots using traditional hematoxylin and eosin (H&E) staining, with particular attention to the ongoing debate surrounding “red” vs. “white” clots. We then discuss white blood cell (WBC) content and its substructure, including neutrophil extracellular traps (NETs). Finally, we highlight emerging molecular approaches, including proteomic, metabolomic, and transcriptomic analyses, which offer new insights into clot characterization and represent the next frontier in this field.

2. A Primer on Stroke Etiology and Clot Pathology

Each stroke subtype reflects a distinct underlying disease process and necessitates a tailored approach for secondary stroke prevention. Because retrieval of clots is only possible for TOAST subtypes resulting in LVO, lacuna strokes and small-vessel disease (SVD) cannot be studied, except in the post-mortem period. Prior studies of SVD have implicated multifocal mechanisms of stroke involving endothelial dysfunction, blood–brain barrier breakdown, and lacunar infarction [17,23,24]. Postmortem analyses have further demonstrated microglial and endothelial activation in affected tissue [25,26,27]. In the context of LVO, the most-encountered etiologies are LAA or CE, which reflect distinct disease processes (Figure 1). As will be discussed in the following section, growing evidence suggests that cryptogenic strokes may share similar mechanisms with CE clots.
Atherosclerosis is characterized by the buildup of fatty atheromatous plaques within blood vessel walls and has a number of well-established epidemiological risk factors, including smoking, hypertension, hyperlipidemia, obesity, and diabetes [28]. In response to a variety of pro-inflammatory signals, the intima, the innermost arterial layer, begins to recruit inflammatory cells, including lipid-laden macrophages or foam cells [29]. Over time, this intimal lesion containing inflammatory cells, smooth muscle, and extracellular matrix may expand into an enlarging atheroma [29]. This accumulation gives rise to a classic lipid-rich, necrotic core [30]. Rupture of the inflammatory caps of vulnerable atheromatous plaques can then expose the inner pro-thrombotic, inflammatory plaque microenvironment to circulating platelets and fibrin, which incites clot formation [29]. In combination with vessel aging [31], subsequent stenosis and impaired vascular dynamics [32], plaque rupture, and thrombus formation can embolize downstream, resulting in LAA LVO.
In contrast to LAA LVO, LVO associated with CE is a result of thromboembolism of a clot generated in the heart. Atrial fibrillation represents the most common etiology of CE and involves impaired coordination of atrial contraction, leading to stasis of blood flow. This stasis, one of the components of Virchow’s triad, predisposes to clot formation, which can then embolize to the intracranial circulation [33]. Hypercoagulability and endothelial dysfunction—the remaining components of Virchow’s triad—may also interact to promote inflammation [34]. While CE shares similarities to LAA, the cardiac environment in which thrombus formation occurs is associated with important differences in biology [35]. Other causes of CE include the presence of a prosthesis such as a mechanical heart valve, or iatrogenic factors such as during cardiac procedures.
Clots retrieved during MT exhibit cellular and molecular profiles that reflect their underlying pathology [36]. On traditional hematoxylin and eosin (H&E) staining, microscopic analysis of extracted clots allows for identification and quantification of cellular clot subcomponents, including red blood cells (RBCs), platelets, white blood cells (WBCs), and coagulation proteins, including fibrin and von Willebrand factor (vWF). Special stains enable detailed WBC subtyping and facilitate the detection of NETs. Transcriptomic signatures within the clots or specific cellular components can be analyzed using RNA sequencing. Protein expressions involved in clot pathogenesis can be quantified through mass spectrometry or other proteomic techniques. Together, these approaches to clot composition provide insight into the underlying pathology and, in turn, uncover clues about the etiologic “past” of each clot [37].

3. Insights from Red Blood Cell, Fibrin, and Platelet Analysis

H&E has long served as the standard approach for composition analysis and has the ability to detect RBCs, fibrin, and platelets, among other components [38]. Traditionally, venous clots were thought to be rich in RBCs (“red clots”) and poor in platelets/fibrin, whereas arterial clots were poor in RBCs and rich in platelets/fibrin (“white clots”) [30]. However, recent studies have revealed that arterial clots can also contain a significant portion of RBCs, and that significant variability exists in the histological appearance and composition of LVO clots [38]. These insights prompted growing research interest in clot composition and its ability to differentiate between different stroke etiologies.
A range of staining techniques and quantification methods have been described in the literature [20]. While the majority of studies utilized H&E staining, Martius blue staining is also commonly used as a more specific technique to assess RBCs and fibrin. Elastica van Gieson, Prussian Blue, and other staining techniques have also been described [21]. Various immunohistochemical (IHC) stains can be used to quantify vWF, fibrin, and other components. For example, RBCs can be selectively quantified via CD235a (glycophorin) antigen [21], while platelets can be labeled with CD41, CD42b, or CD61 [21]. Once staining is completed, quantification is achieved either manually or with the aid of software automation [39].
The distinction between “red” and “white” clots in differentiating between LAA and CE etiologies remains a subject of debate. While some studies reported an increased proportion of RBCs compared to platelets/fibrin (“red clot”) in LAA compared to CE clots, others reported the opposite results [40,41,42]. In recent systematic reviews and meta-analyses, RBCs were found to be more prevalent compared to platelets/fibrin among the LAA clots, whereas CE clots tended to have more platelets/fibrin [39,43]. Significant heterogeneity existed among the included studies, likely owing to differences in staining techniques and reporting, as well as the presence of confounders such as the use of intravenous (IV) thrombolysis and specific MT methods [39,43]. In the most recent large-scale quantitative histological study of 501 clots, Staessens et al. found a statistically significant difference in RBC components between LAA and CE clots, with RBCs comprising 52% in LAA clots vs. 38% in CE clots [40].
On the other hand, an increased presence of platelets/fibrin (“white clot”) has been found to be more common when CE is the underlying etiology. In a meta-analysis from our group, CE clots were found to have approximately 10% more platelets/fibrin compared to LAA clots across the 12 studies included [39]. Similarly, Huang et al. found significantly more platelets/fibrin in the CE clots across the studies included [43]. Significant heterogeneity was again noted across studies [39,43]. Although some studies reported platelets and fibrin separately, many listed combined compositions due to limitations in staining and quantification techniques [39,43]. In the Staessens et al. study, CE clots comprised of 34 ± 17% fibrin and 37 ± 18% platelets, whereas LAA clots only contained 25 ± 13% and 29 ± 14% of these components, respectively [40].
Importantly, many studies have highlighted that the clot composition of cryptogenic stroke tended to mirror that of CE clots [20]. In an analysis of 187 patients with LVO, including 64 with cryptogenic strokes, Sporns et al. found that the composition of cryptogenic stroke was similar to that of CE, and that they both tended to have more fibrin and fewer RBCs compared to LAA clots [44]. Similarly, Boeckh-Behrens et al. studied a cohort of 145 consecutive LVO cases including 36 cryptogenic clots [45]. Platelet/fibrin composition was similar between cryptogenic and CE clots and was greater in proportion compared to non-CE clots. RBCs were again found to comprise a smaller portion of cryptogenic and CE clots compared to non-CE [45]. In their meta-analysis, Huang et al. reported that cryptogenic strokes had fewer RBCs, more fibrin, and no significant difference in platelet content compared to LAA strokes [43]. Staessens et al. found similar relationships between cryptogenic, CE, and LAA clots with regards to platelet and RBC content [40]. They identified significantly more platelets and fewer RBCs in cryptogenic and CE compared to LAA clots, but were not able to detect a statistically significant difference in the fibrin content. These histopathological associations have led to a speculation that cryptogenic strokes may be CE in nature, including atrial fibrillation undetected during the hospital admission or outpatient monitoring [19,40,45]. Although hypothesis-generating, these associations may not reliably predict the etiology of individual clots given considerable heterogeneity even within clots of the same etiologic origin [39,40].
Despite observable differences between CE and LAA clots on H&E at a population scale, their clinical relevance remains limited [39]. This clinical limitation is attributable to relatively minor differences between groups (~10% comparing platelet, RBC, or fibrin composition) and significant intra-group variability [39,40,45,46]. For example, in a study analyzing 662 CE clots and 267 LAA clots, Brinkinji et al. found statistically significant differences in RBC, platelet, and fibrin content between the groups. However, they were unable to define a reliable threshold to differentiate the two etiologies based on H&E analysis alone [46]. Likewise, although Staessens et al. were also able to define differences in H&E clot composition between stroke etiologies, they were unable to create a successful multivariate model that explained stroke etiology based on clot composition [40]. As a result, translating H&E-based differences in clot composition into clinical tools for determining stroke etiology on an individual basis remains challenging [39,40].

4. Insights from White Blood Cells and Neutrophil Extracellular Trap

Inflammation and immune cell infiltration are believed to play a key role in clot formation both in LAA [29] and CE [34]. Various histologic techniques have been employed to identify inflammatory cells within clots retrieved during MT. For instance, CD45 serves as a marker for total WBC content [21], while subtype-specific immunohistochemistry (IHC) staining enables characterization of individual WBC subpopulations. Neutrophil subpopulations can be identified using markers such as neutrophil elastase (NE), neutrophil myeloperoxidase (MPO), or CD66b [21]. CD3 and CD20 are used to label T cells and B cells, respectively, with CD4 and CD8 for their respective T cell subpopulations [21]. Monocytes can be identified using CD14, while CD68 labels both monocytes and macrophages [21]. In addition to cellular markers, neutrophil extracellular trap (NET)—a fibrous structure composed of extracellular DNA released by activated neutrophils—is commonly observed in the stroke clots [47] and can be quantified using IHC staining for citrullinated histone H3 (H3Cit) [21] or via direct extracellular DNA quantification [40]. Table 2 summarizes common techniques used to detect clot compositions and WBC subpopulations.
Total WBC composition has also been investigated for its possible correlation with stroke etiology [38,40,44,46]. In a meta-analysis from our group, a 1% pooled mean difference was found in the total WBC composition between the CE and non-CE/LAA groups, with the CE group containing a statistically higher proportion of WBCs [39]. Although statistically significant, this number is unlikely to be clinically meaningful. On the other hand, the meta-analysis of eight studies by Huang et al. [43] included two studies with conflicting results on the relative enrichment of WBCs in LAA [69] vs. CE clots [44] and reported no statistically significant difference. The majority of original studies failed to detect significant differences in WBC populations [43]. Similar to the trend seen in RBC and platelet/fibrin components where cryptogenic clot mirrored the CE clots, more WBCs were found in cryptogenic vs. LAA clots, although this difference did not reach statistical significance [43]. The results from the Staessens et al. study were in line with previously published literature [39], with more WBCs in CE compared to LAA clots (20 ± 14% vs. 15 ± 14%, respectively) [40]. Interestingly, overall WBC percentages have not been found to be clearly different in the clots of patients with concomitant active cancer [70] or in atypical clots such as fat or septic emboli [71].
The clinical utility of correlating the quantity of WBCs with specific stroke etiologies is limited. However, differentiation of WBC subpopulations has been examined as a potential tool to distinguish between stroke etiologies. Both Sporns et al. [44] and Goebel et al. [52] found a trend towards higher CD68+ monocytes/macrophages in CE clots, while Dargazanli et al. found that CD3+ lymphocytes were more common in LAA clots [66]. Juega et al. reported higher proportions of natural killer (NK) cells and CD4+ T cells, but not CD8+ T cells, in LAA clots [72]. Similarly, Pagola et al. found an increased prevalence of CD4+ T cells in LAA compared to CE clots [73]. Essig et al. and Novotny et al. reported greater neutrophil concentrations in CE clots [58,64]. Thus, CE clots appear to have a greater involvement of innate immune cells such as monocytes, macrophages, and neutrophils, whereas LAA clots tend to have greater lymphocytic infiltration. These conclusions are supported by a recent study by Jabrah et al., who found that LAA clots had increased lymphocytic infiltration compared to both CE and cryptogenic clots, whereas CE clots had increased CD66b+ neutrophils [74]. Of note, increasing evidence highlights the importance of adhesion molecules (e.g., E-selectin, P-selectin, and L-selectin) in mediating thrombosis and inflammation. For example, E-selectin, expressed exclusively on endothelial cells, was found to be upregulated in ischemic vasculature shortly after reperfusion [75]. P-selectin, on the other hand, mediates the interplay between platelets and leukocytes on activated endothelial cells [76] and shows distinct spatial organization within AIS clots: P-selectin-positive platelets were concentrated in the core, whereas less dense P-selectin-negative platelets were found to be located in the shell [77,78]. Although a full discussion of these adhesion molecules is beyond the scope of this review, the primary literature offers important insights into their crucial roles and is well worth further reading. Table 3 summarizes the current evidence to date on WBC subpopulations in LAA and CE clots.
In the past decade, NETs have been widely implicated as a contributor to thrombosis [20,47,79]. NET formation, known as “NETosis,” involves localization of pro-coagulant factors and histone citrullination, which leads to decondensation of the nuclear chromatin and subsequent release of fibrous extracellular network [80,81,82]. Originally identified as a neutrophil-mediated immunity, this process forms a scaffold that facilitates platelets and RBC aggregation, and has been implicated in the formation of both venous and arterial clots [82]. Platelet activation, in part modulated through P-selectin, accelerates NETosis and contributes to inflammation, thrombosis, and ischemic injury [83]. NET burden was found to be associated with increased inflammation in the left atrium [37,84,85], predisposing to clot formation and subsequent cardioembolism. In a recent study, NET formation represented a key source of extracellular DNA that triggered activation of the AIM2 (Absent in melanoma 2, a dsDNA-triggered) inflammasome after an initial stroke [86]. In turn, increased inflammation in vulnerable plaques leads to arterial embolism and recurrent stroke. Remarkably, elimination of extracellular DNA by DNase treatment has been shown to promote ex vivo clot lysis [47] and reduce the rate of stroke recurrence after experimental stroke [86]. This leads some authors to speculate whether DNase treatment administration with IV thrombolysis could potentially be beneficial in patients with CE LVO [40]. Although there are inconsistencies in the reported neutrophil content between CE and LAA clots [58,64,74], NETs and extracellular DNA have been consistently reported in greater quantity in CE compared to LAA clots across a number of studies [20,40,47,58]. Furthermore, NETs appear to exhibit a more peripheral, organized distribution in CE clots, as opposed to the more diffuse pattern seen in LAA clots [74]. The presence of NETs also serves as an indicator of age [37,47,87], with fresh clot containing less NETs, which increases in content as the clot matures [47,87]. Because fresh clot is typically associated with improved thrombolysis in cerebral infarction scores (TICI) and decreased procedural time [87], it is not surprising that the presence of NETs has been shown to be associated with worse outcome [58]. The increased presence of NETs in CE clots may reflect underlying differences in pathogenesis across stroke etiologies. One possible explanation is that CE clots may have greater exposure to NETosis and NET formation prior to embolization, whereas LAA clots may form more acutely in the setting of plaque rupture, resulting in comparatively less NET formation. These insights remain speculative and require additional validation.

5. Molecular and Next-Generation Analysis

The repertoire of techniques for analyzing clinical pathology specimens has undergone marked expansion in the past decade. The field of LVO clots, in particular, is increasingly moving beyond conventional histology and toward molecular and next-generation techniques, which enable more detailed and comprehensive tissue characterization [88]. These advancements, particularly in individual -omic and multiomic approaches, offer substantial potential to revolutionize our understanding of clot composition and underlying stroke etiology [88].
Although promising, literature on -omic and multiomic approaches remains limited, with most studies including only small patient cohorts. To ensure a comprehensive review of the available data, we searched the MEDLINE and EMBASE databases (query date: 23 August 2025) using the MeSH/Emtree terms “Ischemic stroke” combined with “Thrombectomy” (or “Mechanical Thrombectomy for Emtree) and [“Metabolomics” or “Proteomics” or “Gene Expression Profiling” (MeSH term for transcriptomic)]. Titles and abstracts were screened for relevance to stroke etiology, and the results were cross-referenced with the most recent review on the subject [88] to ensure completeness.

5.1. Proteomics

Proteomic analysis utilizes global and targeted mass spectrometry to quantify the levels of proteins in a sample. Individual protein levels can be then compared, or bioinformatic analyses can be applied to identify patterns of protein activation or suppression [89]. Proteomics has been utilized to detect the proteins and protein–protein interactions involved in the pathogenesis of stroke clots [90], as well as associations of different proteins to a variety of clinical features including fibrinolytic activity [91].
Several studies have employed proteomic techniques to attempt to find connections between protein level patterns and stroke etiology. Darganzanli et al. applied mass spectrometry and machine learning to identify proteomic distinguishing LAA from CE clots [92]. They found that coagulation factor XIII, which catalyzes the last step of the coagulation cascade, was most consistently different between the two etiologies. When combined with a history of cardiac failure, a trio of proteins (coagulation factor XIII, eukaryotic translation initiation factor 2 subunit 3, and Ras GTPase-activating-like protein IQGAP2) yielded a classification accuracy of 97% [92]. Rossi et al. conducted a similar analysis and identified 14 proteins with significantly different concentrations between the two etiologies [93]. Four proteins involved in the ubiquitin–proteasome pathway, coagulation, or plasminogen activation were enriched in LAA clots, whereas ten proteins involved in the ubiquitin–proteasome pathway, cytoskeletal remodeling of platelets, platelet adhesion, and coagulation were more abundant in CE clots. In a recent proteomic analysis, Kim et al. found a number of proteins and pathways that were specifically upregulated in LAA clots, CE clots, cancer-related clots, and cryptogenic clots [94]. Similarly, they found elevated levels of proteins involved in the thrombosis and hemostasis pathway (PLEK, ROCK2, TLN1, and RAB14) in CE clots, whereas proteins involved in the ubiquitin–proteasome pathway and atherosclerosis progression (e.g., CD59, LAMP1, and ELANE) were found in abundance in LAA clots. Other studies examining the relationship between proteomics and stroke etiology are detailed in Table 4. A major limitation across these investigations lies in the difficulty of translating proteomic analyses to laboratory tools available in the clinical setting. Moreover, the small size (or absence) of an external validation cohort currently restricts their clinical applicability.

5.2. Metabolomics

Rooted in systems biology, metabolomics is the study of small-molecule metabolites and lipids, which is performed after larger proteins are separated from the samples. While peripheral metabolomic profiling in stroke has been widely studied, LVO-specific metabolomic analysis remains in its early stages, with only few publications to date [88,95]. Using liquid chromatography–mass spectrometry, Martha et al. analyzed five clots and identified the top ten most frequent metabolites as various glycerophospholipids and fatty acids [96]. Li et al. utilized quadrupole time-of-flight mass spectrometry and identified six metabolites that, when combined with a machine learning random forest classifier, yielded a predictive model with an area under the curve (AUC) of 0.89 [97]. The metabolites enriched in LAA clots were diglyceride (DG) (18:3/24:0), DG (22:0/24:0), phytosphingosine, and galabiosylceramide (18:1/24:1); while those enriched in CE clots were triglyceride (15:0/16:1/o-18:0) and glucosylceramide (18:1/24:0). Using H&E and IHC, Osakada et al. identified a localized pattern with 4-hydroxyl-2-nonenal, an oxidative stress marker, in LAA clots [98]. Suissa et al. combined proteomics and metabolomics to analyze 59 clots [99]. Their proteomic analysis revealed elevated levels of fibrinogens α, β, γ—components of fibrin—in CE clots, consistent with prior histologic findings. Interestingly, glycophorin-A, a marker for RBCs, was also significantly more abundant in CE clots. Using an integrated proteomic and metabolomic approach, the authors developed a predictive model with 100% sensitivity and 85.7% specificity in distinguishing CE from LAA clots. Furthermore, in cases initially classified as cryptogenic, the model predicted a CE source in all patients who were later diagnosed with atrial fibrillation at their 3-month follow-up.
Table 4 summarizes the available literature pertaining to LVO etiologies and proteomic and/or metabolomic analyses.
Table 4. Literature on stroke etiologies and clot proteomics/metabolomics.
Table 4. Literature on stroke etiologies and clot proteomics/metabolomics.
ReferenceSample SizeTechniqueFindings
Darganzanli, 2020 [92]60
(32 CE, 28 LAA)		Proteomic with Nano- LC-MS.
Dataset then analyzed using support vector machine (SVM) learning method.		Protein trios allowing 88% accuracy of correct classification are coagulation factor XIII +
  • eukaryotic translation initiation factor 2 subunit 3 & Ras GTP-ase-activating-like protein IQGAP2.
  • F-actin-capping protein & myosin light chain kinase.
  • Septin-7 & gamma-adducin.
When integrating protein trio 1 + history of cardiac failure + protein concentration, the accuracy improved to 97%.
Specific limitations:
Proof-of-concept study. Does not include external validation.
Suissa, 2021 [99]41 (34 CE, 7 LAA)Multiomic (combined proteomic and metabolomic approach) Using the combined proteomic and metabolomic signature, the authors’ model achieved 100% sensitivity and 85.7% specificity of predicting CE source. External validation performed on patients initially classified as cryptogenic achieved 100% prediction in the rate of new atrial fibrillation diagnosis at 3 months.
Specific limitations:
Small validation cohort (7 patients).
Abbasi, 2021 [100] 48 (25 CE, 23 LAA)Proteomic with RPPACE clots have more diverse and abundant protein linkages between PPAR-gamma and arginase-1, CD63, CD234, PKCαβ Thr 638/641, and vWF.
Specific limitations:
Descriptive observational findings only. Does not include predictive modeling.
Lopez-Pedrera, 2023 [101]18 (9 CE, 9 LAA)Proteomic with nano-LC-MS26 proteins were differentially abundant between CE and LAA clots:
-
CE: predominance of Protein S100-P, vitronectin, ceruloplasmin, clusterin, histone cluster 2 H3 family member a, 26S proteasome regulatory subunit 10B, antithrombin-III, 26S proteasome regulatory subunit 4, glutamate-cysteine ligase regulatory subunit, elongation factor Tu, mitochondrial, alpha-1-antichymotrypsin, U6 snRNA-associated Sm-like protein LSm2, apolipoprotein A-I, C-1-tetrahydrofolate synthase, cytoplasmic, 6-phosphogluconolactonase, elongation factor 1-alpha 1, small ribosomal subunit protein uS3, S-formylglutathione hydrolase, adenine phosphoribosyltransferase, nucleosome assembly protein 1-like 1.
-
LAA: predominance of ubiquitin-like-conjugating enzyme ATG3, blood group Rh(D) polypeptide, fibrinogen alpha chain, solute carrier family 2, facilitated glucose transporter member 1, keratin type II cytoskeletal 1, chloride intracellular channel protein 4.
Specific limitations:
Descriptive observational findings only. Does not include predictive modeling or external validation.
Li, 2023 [97]48 (26 CE, 22 LAA)Metabolomic with UPLC-QTOF-MS6 metabolites were differentially abundant in CE and LAA clots and selected by machine learning model:
-
CE: TG (15:0/16:1/o-18:0) and glucosylceramide (18:1/24:0).
-
LAA: DG (18:3/24:0), DG (22:0/24:0), phytosphingosine, and galabiosylceramide (18:1/24:1).
Random forest model achieved AUC of 0.89 for discriminating between CE and LAA origins in the external validation cohort.
Specific limitations:
Validation cohort does not include cryptogenic patients, only those with LAA and CE clots.
Rossi, 2022 [93]31 (16 CE, 15 LAA)Proteomic with LC-MS/MS14 proteins were differentially abundant between CE and LAA clots:
-
CE: myosin-9, coronin-1C, actin-related protein 2/3 complex subunit 2, platelet glycoprotein Ib alpha chain, platelet glycoprotein IX, protein disulfide-isomerase A6, Valosin-containing protein (VCP), ubiquitin-like modifier-activating enzyme 1, coagulation factor XIII A chain, Ras-related protein RAB-27B
-
LAA: ubiquitin-60S ribosomal protein L40, ubiquitin-conjugating enzyme E2, ubiquitin-conjugating enzyme E2 variant 1, and fibrinogen alpha chain.
Specific limitations:
Descriptive observational findings only. Does not include predictive modeling or external validation.
Kim, 2025 [94]27 (17 CE, 6 LAA, 4 CR)Proteomic with LC-MS/MS
-
Proteins upregulated in CE clots are involved in actin cytoskeleton organization, supramolecular fiber organization, platelet aggregation, hemostasis, coagulation, apoptotic processes, and the tricarboxylic cycle.
-
Proteins upregulated in LAA clots are involved in ubiquitination, ubiquitin-proteasome system, endothelial migration, and atheroma formation.
Using machine learning, the predictive model has a PPV of 75% in predicting etiology in the cryptogenic/undetermined group during the follow-up period.
Specific limitations:
Lower PPV, with a small validation cohort (8 patients).
CE, cardioembolic; CR, cancer-related; DG, diglyceride; LAA, large-artery atherosclerosis; LC, liquid chromatography; MS, mass spectrometry; PPV, positive predictive value; RPPA, reverse-phase protein array; TG, triglyceride; UPLC-QTOF-MS, ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry; vWF, von Willebrand factor.

5.3. Transcriptomics

Transcriptomic analysis uses next-generation sequencing to quantify mRNA levels and measure gene expression profiles. This approach has been greatly advanced by exploration into genetic determinants of AIS. In particular, genome-wide association studies (GWAS) have demonstrated correlation of specific genetic loci with stroke etiology, risk factors, and long-term functional outcome [102,103,104]. These studies have identified key transcriptional pathways implicated in atrial fibrillation, inflammation, lipid metabolism, and vascular remodeling, all with significant associations with AIS [104]. For instance, two genes involved in cardiac development, PITX2 and ZFHX3, have been consistently associated with atrial fibrillation and an increased incidence of CE strokes [103,104]. Such genetic insights can, in turn, be leveraged to guide transcriptomic analyses of retrieved clots to enable interrogation of specific pathways linked to the genes of interest [105]. Transcriptomic expression profiles can be defined for a sample as a whole (bulk RNA-seq), segregated into single cells (scRNA-seq), or spatially within a sample (spRNA-seq). The ”big data” generated from such methods is then analyzed according to known gene expression clusters or pathways to dissect the patterns of activation or inhibition in specific disease contexts [106].
In an early effort to use mRNA profiling to differentiate stroke etiology, Baek et al. used quantitative real-time polymerase chain reactions on 82 MT clots, focusing on gene expression markers for inflammation [105]. They found that IL-1β, a cytokine whose release can be triggered by local inflammasomes, was upregulated in the nine LAA cases. In a more recent analysis, Tutino et al. used bulk RNA-seq to analyze 38 clots [107]. They found that LAA clots tended to have stronger expressions of genes involved in oxidoreduction and T cell signaling, whereas CE clots had much denser expression of immunological pathways involving neutrophils and myeloid leukocytes. This trend in gene ontology, where LAA clots tend to feature more adaptive immunity activation and CE clots more innate immunity activation, closely aligns with the WBC subcomponent analyses previously discussed [43,73]. Interestingly, cryptogenic clots did not necessarily cluster towards either the LAA or CE expression, possibly suggesting heterogenous etiology [107].
In a recent work from our group, LAA clots were found to be enriched in B cells, CD4+ T cells, dendritic cells, and macrophages [108]. Conversely, CE clots had more CD8+ T cells, monocytes, NK cells, and neutrophils. Using scRNA-seq, we found that CE clots had upregulation of genes involved in signaling pathways related to immunogenic cell death, Th1, RHOA, actin nucleation by ARP-WASP complex, ILK, NET, and hepatic fibrosis, in all cell types. On the other hand, macrophages from LAA clots showed upregulation of the Th1 pathway, multiple sclerosis signaling pathway, and phagosome formation, while CD8+ T cells from CE clots were enriched in PD-1, PD-L1 cancer immunotherapy, and CTLA4 signaling. Beyond predicting stroke etiology, Santo et al. identified 25 differentially expressed genes from the transcriptome data to be significant predictors of 90-day mRS [109]. In a subsequent study, the same group achieved 94% accuracy in predicting good long-term outcomes using a hybrid model integrating histomic. and transcriptomic clot features [110]. Table 5 summarizes the available literature pertaining to LVO etiologies and transcriptomic analyses.
Compared to conventional histology, -omic and multiomic approaches promise superior sensitivity and specificity in distinguishing stroke etiologies, particularly when integrated with machine learning and clinical data. However, this field remains in its early stages, and external validation in larger cohorts is required to clarify the clinical utility of these approaches. From a practical standpoint, the high cost, extended processing time, and limited availability (primarily restricted to select academic centers), pose significant barriers to widespread clinical adoption. Continued advancement in technology, protocol standardization, and access will be essential in translating these promising approaches into routine clinical practice.

6. Summary of Current Evidence

A review of the current literature allows several observations regarding the relationship between clot composition and stroke etiology (Figure 2, Table 6). Clots from LAA tend to have greater RBCs on histological analysis than those of CE origin [39]. Conversely, CE clots tend to have a greater proportion of fibrin and platelets [39]. Findings on total WBC content between the two etiologies are conflicting, with any reported statistically significant differences too small to be clinically meaningful [39]. When WBC subpopulations are considered, CE clots tend to have greater representation of innate immunity such as neutrophils [64] and monocytes [44], whereas LAA clots have a greater lymphocytic filtration [74]. Similarly, CE clots have more NETs [74] and extracellular DNA [40]. In terms of gene expression, CE clots demonstrate upregulation of genes involved in inflammation and neutrophil activity [107], while LAA clots are characterized by T cell and oxidative signaling [107]. Although results are promising in metabolomics and proteomics, several studies to date have yet to produce common pathways that definitively differentiate clot etiologies [88,92,94].
Several studies using conventional histology have shown that cryptogenic clots share features more consistent with CE clots [20], including a greater quantity of platelets and fibrin and lower RBCs [40]. This has led to the speculation in several studies that cryptogenic strokes may reflect undiagnosed cardioembolic events [20,40,45], including atrial fibrillation not discovered during the hospital stay [19]. However, these trends are not universal across studies and have not been clearly supported by analyses of WBC subcomponents [43] or transcriptomic [107] or proteomic profiles [88].

7. Limitations and Future Directions

Although clot composition analysis offers a promising avenue for investigating stroke etiology, several challenges currently limit its routine clinical application. First, the pro-thrombotic large-artery and cardiac environments may lead to the formation of clots that appear morphologically, histologically, and even molecularly similar [111]. Second, clots formed by a similar etiology can demonstrate significant variability in all of these categories [39]. Third, spatial heterogeneity within the clots, whether intrinsic or secondary to endovascular intervention, may confound interpretation of clot composition [112]. Finally, inherent methodological limitations constrain the utility of clot composition analysis. Several studies suggest that RBC-rich clots are more susceptible to fibrinolysis, likely due to improved drug penetration within the loosely organized RBC clusters compared to platelet/fibrin-rich clots [49,113,114,115,116]. Such clots may lyse before they can be retrieved via MT. On the other hand, stroke due to small-vessel disease and highly recalcitrant clots that withstand both fibrinolysis and MT also remain unavailable for analysis. Because clot composition studies are inherently restricted to specimens retrievable via MT, our current understanding is shaped by only a subset of clots resistant to fibrinolysis yet amenable to mechanical extraction. This selection bias may result in overrepresentation of certain structural and molecular features and underrepresentation of others. Moreover, fibrinolysis itself may alter the composition of successfully retrieved clots, further confounding the interpretation [20].
To date, multiomic data have shown the greatest promise in predicting stroke etiology. Machine learning offers a powerful means of handling the computational demands of pattern recognition and trend detection inherent to these large, complex datasets. In the future, such approaches could integrate the full spectrum of data from a given clot (histologic, proteomic, metabolomic, and/or transcriptomic) and apply established LAA and CE signatures to aid in classification. Importantly, these models could be designed to account for inherent heterogeneity within the stroke subtypes and improve diagnostic specificity. Early studies have already demonstrated high accuracy in differentiating LAA from CE clots and in reclassifying some cryptogenic strokes as CE. Although barriers such as cost, processing time, and limited availability currently preclude bedside implementation, continued advances in these areas may allow integrated profiles to become a clinically deployable tool for routine clinical decision-making.
Beyond determining stroke etiology, clot composition analysis is increasingly explored for a range of clinical applications. Multiple studies have examined associations between clot histology and both acute recanalization success [37,69] and long-term outcomes [43,58,109,110]. Others have investigated correlations between radiologic clot characteristics and histologic and molecular features [117,118,119]. For example, Hyperdense Artery Sign (HAS) on non-contrasted CT has demonstrated correlation with RBC-rich phenotype and improved recanalization rates [117]. On MRI, Susceptibility Vessel Sign (SVS), representing hypointensity at the site of the clot, has been shown to be associated with lower platelet content and improved functional outcome [118]. However, a recent large study of 1430 patients found no significant association between clot composition and MT efficacy [120]. In contrast, novel imaging techniques such as oxygen extraction fraction mapping and quantitative susceptibility mapping do not focus on the clot itself but on tissue-level changes that may relate to stroke etiology and its recovery potential [121]. Together, these analyses advance our understanding of the molecular and cellular mechanisms underlying stroke pathophysiology [30,90], with potential implications for biomarker discovery, secondary prevention, and the development of targeted therapeutics [88,89,90,111,122].

8. Conclusions

Clot composition analysis, particularly through the use of next-generation -omic and multiomic approaches, offers a novel opportunity to examine the underlying pathology and etiologic “story” of each clot. By providing molecular and structural insights, these approaches can illuminate the mechanisms of clot formation and inform more precise strategies for secondary stroke prevention. Growing evidence of distinct compositional differences between LAA and CE clots strengthens our understanding of these entities and underscores the diagnostic value of clot profiling. In cryptogenic stroke, where conventional workup often falls short, clot analysis holds promise as an adjunctive tool to identify occult etiologies and guide targeted interventions, including anticoagulation. Taken together, these findings position clot composition analysis as an emerging bridge between specimen analysis and actionable, personalized stroke care.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Collaborators, G.B.D.S. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021, 20, 795–820. [Google Scholar] [CrossRef]
  2. Hilkens, N.A.; Casolla, B.; Leung, T.W.; de Leeuw, F.-E. Stroke. Lancet 2024, 403, 2820–2836. [Google Scholar] [CrossRef]
  3. De Los Rios, F.; Kleindorfer, D.O.; Guzik, A.; Ortega-Gutierrez, S.; Sangha, N.; Kumar, G.; Grotta, J.C.; Lee, J.M.; Meyer, B.C.; Schwamm, L.H.; et al. Intravenous fibrinolysis eligibility: A survey of stroke clinicians’ practice patterns and review of the literature. J. Stroke Cerebrovasc. Dis. 2014, 23, 2130–2138. [Google Scholar] [CrossRef][Green Version]
  4. Wu, N.; Doeppner, T.R.; Hermann, D.M.; Gronewold, J. Efficacy and safety of intravenous tenecteplase compared to alteplase before mechanical thrombectomy in acute ischemic stroke: A meta-analysis. J. Neurol. 2024, 271, 3928–3941. [Google Scholar] [CrossRef]
  5. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418. [Google Scholar] [CrossRef]
  6. Zhao, H.; Coote, S.; Pesavento, L.; Churilov, L.; Dewey, H.M.; Davis, S.M.; Campbell, B.C.V. Large Vessel Occlusion Scales Increase Delivery to Endovascular Centers Without Excessive Harm from Misclassifications. Stroke 2017, 48, 568–573. [Google Scholar] [CrossRef] [PubMed]
  7. Dozois, A.; Hampton, L.; Kingston, C.W.; Lambert, G.; Porcelli, T.J.; Sorenson, D.; Templin, M.; VonCannon, S.; Asimos, A.W. PLUMBER Study (Prevalence of Large Vessel Occlusion Strokes in Mecklenburg County Emergency Response). Stroke 2017, 48, 3397–3399. [Google Scholar] [CrossRef] [PubMed]
  8. Jadhav, A.P.; Desai, S.M.; Jovin, T.G. Indications for Mechanical Thrombectomy for Acute Ischemic Stroke: Current Guidelines and Beyond. Neurology 2021, 97 (Suppl. S2), S126–S136. [Google Scholar] [CrossRef] [PubMed]
  9. Berkhemer, O.A.; Fransen, P.S.S.; Beumer, D.; van den Berg, L.A.; Lingsma, H.F.; Yoo, A.J.; Schonewille, W.J.; Vos, J.A.; Nederkoorn, P.J.; Wermer, M.J.H.; et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 2015, 372, 11–20. [Google Scholar] [CrossRef] [PubMed]
  10. Campbell, B.C.V.; Mitchell, P.J.; Kleinig, T.J.; Dewey, H.M.; Churilov, L.; Yassi, N.; Yan, B.; Dowling, R.J.; Parsons, M.W.; Oxley, T.J.; et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 2015, 372, 1009–1018. [Google Scholar] [CrossRef]
  11. Goyal, M.; Demchuk, A.M.; Menon, B.K.; Eesa, M.; Rempel, J.L.; Thornton, J.; Roy, D.; Jovin, T.G.; Willinsky, R.A.; Sapkota, B.L.; et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 2015, 372, 1019–1030. [Google Scholar] [CrossRef] [PubMed]
  12. Jovin, T.G.; Chamorro, A.; Cobo, E.; de Miquel, M.A.; Molina, C.A.; Rovira, A.; San Román, L.; Serena, J.; Abilleira, S.; Ribó, M.; et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. 2015, 372, 2296–2306. [Google Scholar] [CrossRef] [PubMed]
  13. Saver, J.L.; Goyal, M.; Bonafe, A.; Diener, H.-C.; Levy, E.I.; Pereira, V.M.; Albers, G.W.; Cognard, C.; Cohen, D.J.; Hacke, W.; et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. 2015, 372, 2285–2295. [Google Scholar] [CrossRef]
  14. Albers, G.W.; Marks, M.P.; Kemp, S.; Christensen, S.; Tsai, J.P.; Ortega-Gutierrez, S.; McTaggart, R.A.; Torbey, M.T.; Kim-Tenser, M.; Leslie-Mazwi, T.; et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N. Engl. J. Med. 2018, 378, 708–718. [Google Scholar] [CrossRef] [PubMed]
  15. Nogueira, R.G.; Jadhav, A.P.; Haussen, D.C.; Bonafe, A.; Budzik, R.F.; Bhuva, P.; Yavagal, D.R.; Ribo, M.; Cognard, C.; Hanel, R.A.; et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N. Engl. J. Med. 2018, 378, 11–21. [Google Scholar] [CrossRef]
  16. Olthuis, S.G.H.; Pirson, F.A.V.; Pinckaers, F.M.E.; Hinsenveld, W.H.; Nieboer, D.; Ceulemans, A.; Knapen, R.R.M.M.; Robbe, M.M.Q.; Berkhemer, O.A.; van Walderveen, M.A.A.; et al. Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: A multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet 2023, 401, 1371–1380. [Google Scholar] [CrossRef]
  17. Adams, H.P., Jr.; Bendixen, B.H.; Kappelle, L.J.; Biller, J.; Love, B.B.; Gordon, D.L.; Marsh, E.E., 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24, 35–41. [Google Scholar] [CrossRef]
  18. Knight-Greenfield, A.; Nario, J.J.Q.; Gupta, A. Causes of Acute Stroke: A Patterned Approach. Radiol. Clin. N. Am. 2019, 57, 1093–1108. [Google Scholar] [CrossRef]
  19. Ibeh, C.; Elkind, M.S.V. Stroke Prevention After Cryptogenic Stroke. Curr. Cardiol. Rep. 2021, 23, 174. [Google Scholar] [CrossRef]
  20. Bacigaluppi, M.; Semerano, A.; Gullotta, G.S.; Strambo, D. Insights from thrombi retrieved in stroke due to large vessel occlusion. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow. Metab. 2019, 39, 1433–1451. [Google Scholar] [CrossRef]
  21. Aliena-Valero, A.; Baixauli-Martín, J.; Torregrosa, G.; Tembl, J.I.; Salom, J.B. Clot Composition Analysis as a Diagnostic Tool to Gain Insight into Ischemic Stroke Etiology: A Systematic Review. J. Stroke 2021, 23, 327–342. [Google Scholar] [CrossRef] [PubMed]
  22. Shekhtman, O.; Sioutas, G.S.; Piavchenko, G.; Bhalla, S.; Cooke, D.L.; Winkler, E.; Burkhardt, J.-K.; Srinivasan, V.M. Endovascular biopsy in neurointerventional surgery: A systematic review. Interv. Neuroradiol. 2024, 15910199241240508. [Google Scholar] [CrossRef] [PubMed]
  23. Gao, Y.; Li, D.; Lin, J.; Thomas, A.M.; Miao, J.; Chen, D.; Li, S.; Chu, C. Cerebral small vessel disease: Pathological mechanisms and potential therapeutic targets. Front. Aging Neurosci. 2022, 14, 961661. [Google Scholar] [CrossRef]
  24. Shi, Y.; Wardlaw, J.M. Update on cerebral small vessel disease: A dynamic whole-brain disease. Stroke Vasc. Neurol. 2016, 1, 83–92. [Google Scholar] [CrossRef]
  25. Fernando, M.S.; O’Brien, J.T.; Perry, R.H.; English, P.; Forster, G.; McMeekin, W.; Slade, J.Y.; Golkhar, A.; Matthews, F.E.; Barber, R.; et al. Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol. Appl. Neurobiol. 2004, 30, 385–395. [Google Scholar] [CrossRef]
  26. Simpson, J.E.; Fernando, M.S.; Clark, L.; Ince, P.G.; Matthews, F.; Forster, G.; O’Brien, J.T.; Barber, R.; Kalaria, R.N.; Brayne, C.; et al. White matter lesions in an unselected cohort of the elderly: Astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol. Appl. Neurobiol. 2007, 33, 410–419. [Google Scholar] [CrossRef]
  27. Simpson, J.E.; Ince, P.G.; Higham, C.E.; Gelsthorpe, C.H.; Fernando, M.S.; Matthews, F.; Forster, G.; O’Brien, J.T.; Barber, R.; Kalaria, R.N.; et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol. Appl. Neurobiol. 2007, 33, 670–683. [Google Scholar] [CrossRef]
  28. Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 2006, 47, C7–C12. [Google Scholar] [CrossRef]
  29. Libby, P. The changing landscape of atherosclerosis. Nature 2021, 592, 524–533. [Google Scholar] [CrossRef]
  30. Weisel, J.W.; Litvinov, R.I. Exploring the thrombus niche: Lessons learned and potential therapeutic opportunities. Blood 2025, 2024025319. [Google Scholar] [CrossRef] [PubMed]
  31. Spronk, H.M.H.; Padro, T.; Siland, J.E.; Prochaska, J.H.; Winters, J.; van der Wal, A.C.; Posthuma, J.J.; Lowe, G.; d’Alessandro, E.; Wenzel, P.; et al. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thromb. Haemost. 2018, 118, 229–250. [Google Scholar] [CrossRef]
  32. Tiedt, S.; Buchan, A.M.; Dichgans, M.; Lizasoain, I.; Moro, M.A.; Lo, E.H. The neurovascular unit and systemic biology in stroke—Implications for translation and treatment. Nat. Rev. Neurol. 2022, 18, 597–612. [Google Scholar] [CrossRef]
  33. Ding, W.Y.; Gupta, D.; Lip, G.Y.H. Atrial fibrillation and the prothrombotic state: Revisiting Virchow’s triad in 2020. Heart (British Cardiac Society) 2020, 106, 1463–1468. [Google Scholar] [CrossRef]
  34. Hu, Y.-F.; Chen, Y.-J.; Lin, Y.-J.; Chen, S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 2015, 12, 230–243. [Google Scholar] [CrossRef]
  35. Martinod, K.; Claessen, A.; Martens, C.; Krauel, K.; Velásquez Pereira, L.C.; Witsch, J.; Witsch, T. NET burden in left atrial blood is associated with biomarkers of thrombosis and cardiac injury in patients with enlarged left atria. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2025, 114, 112–125. [Google Scholar] [CrossRef]
  36. Mereuta, O.M.; Agarwal, T.; Ghozy, S.; Dai, D.; Arul, S.; Brinjikji, W.; Kallmes, D.F.; Kadirvel, R. Shell Versus Core Architecture and Biology of Thrombi in Acute Ischemic Stroke: A Systematic Review. Clin. Appl. Thromb. Hemost. 2023, 29, 10760296231213632. [Google Scholar] [CrossRef]
  37. Marta-Enguita, J.; Machado, F.J.D.; Orbe, J.; Muñoz, R. Thrombus composition and its implication in ischemic stroke assessment and revascularization treatments. Neurol. (Engl. Ed.) 2025, 40, 77–88. [Google Scholar] [CrossRef]
  38. Ahn, S.H.; Hong, R.; Choo, I.S.; Heo, J.H.; Nam, H.S.; Kang, H.G.; Kim, H.W.; Kim, J.H. Histologic features of acute thrombi retrieved from stroke patients during mechanical reperfusion therapy. Int. J. Stroke 2016, 11, 1036–1044. [Google Scholar] [CrossRef] [PubMed]
  39. Sujijantarat, N.; Templeton, K.A.; Antonios, J.P.; Renedo, D.; Koo, A.B.; Haynes, J.O.; Fathima, B.; Amllay, A.; Nowicki, K.; Huttner, A.; et al. Is Clot Composition Associated with Cause of Stroke? A Systematic Review and Meta-Analysis. Stroke Vasc. Interv. Neurol. 2024, 4, e001426. [Google Scholar] [CrossRef]
  40. Staessens, S.; Vandelanotte, S.; François, O.; Boulleaux, E.; Bretzner, M.; Casolla, B.; Corseaux, D.; Puy, L.; Denorme, F.; De Wilde, M.; et al. Association Between Thrombus Composition and Etiology in Patients with Acute Ischemic Stroke Treated by Thrombectomy. Stroke 2025, 56, 1026–1035. [Google Scholar] [CrossRef] [PubMed]
  41. Hashimoto, T.; Hayakawa, M.; Funatsu, N.; Yamagami, H.; Satow, T.; Takahashi, J.C.; Nagatsuka, K.; Ishibashi-Ueda, H.; Kira, J.-i.; Toyoda, K. Histopathologic Analysis of Retrieved Thrombi Associated with Successful Reperfusion After Acute Stroke Thrombectomy. Stroke 2016, 47, 3035–3037. [Google Scholar] [CrossRef]
  42. Chen, R.; Zeng, X.; Liu, Y.; Huang, C.; Yang, J. No Histological Difference between Large Atherosclerotic and Cardiogenic Embolic Thrombus. Oxidative Med. Cell. Longev. 2022, 2022, 4845264. [Google Scholar] [CrossRef]
  43. Huang, J.; Killingsworth, M.C.; Bhaskar, S.M.M. Is Composition of Brain Clot Retrieved by Mechanical Thrombectomy Associated with Stroke Aetiology and Clinical Outcomes in Acute Ischemic Stroke?—A Systematic Review and Meta-Analysis. Neurol. Int. 2022, 14, 748–770. [Google Scholar] [CrossRef]
  44. Sporns, P.B.; Hanning, U.; Schwindt, W.; Velasco, A.; Minnerup, J.; Zoubi, T.; Heindel, W.; Jeibmann, A.; Niederstadt, T.U. Ischemic Stroke: What Does the Histological Composition Tell Us About the Origin of the Thrombus? Stroke 2017, 48, 2206–2210. [Google Scholar] [CrossRef]
  45. Boeckh-Behrens, T.; Kleine, J.F.; Zimmer, C.; Neff, F.; Scheipl, F.; Pelisek, J.; Schirmer, L.; Nguyen, K.; Karatas, D.; Poppert, H. Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. Stroke 2016, 47, 1864–1871. [Google Scholar] [CrossRef] [PubMed]
  46. Brinjikji, W.; Nogueira, R.G.; Kvamme, P.; Layton, K.F.; Delgado Almandoz, J.E.; Hanel, R.A.; Mendes Pereira, V.; Almekhlafi, M.A.; Yoo, A.J.; Jahromi, B.S.; et al. Association between clot composition and stroke origin in mechanical thrombectomy patients: Analysis of the Stroke Thromboembolism Registry of Imaging and Pathology. J. NeuroInterv. Surg. 2021, 13, 594–598. [Google Scholar] [CrossRef]
  47. Laridan, E.; Denorme, F.; Desender, L.; François, O.; Andersson, T.; Deckmyn, H.; Vanhoorelbeke, K.; De Meyer, S.F. Neutrophil extracellular traps in ischemic stroke thrombi. Ann. Neurol. 2017, 82, 223–232. [Google Scholar] [CrossRef] [PubMed]
  48. Fitzgerald, S.; Wang, S.; Dai, D.; Murphree, D.H., Jr.; Pandit, A.; Douglas, A.; Rizvi, A.; Kadirvel, R.; Gilvarry, M.; McCarthy, R.; et al. Orbit image analysis machine learning software can be used for the histological quantification of acute ischemic stroke blood clots. PLoS ONE 2019, 14, e0225841. [Google Scholar] [CrossRef]
  49. Choi, M.H.; Park, G.H.; Lee, J.S.; Lee, S.E.; Lee, S.J.; Kim, J.H.; Hong, J.M. Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke. Stroke 2018, 49, 652–659. [Google Scholar] [CrossRef] [PubMed]
  50. Di Meglio, L.; Desilles, J.P.; Ollivier, V.; Nomenjanahary, M.S.; Di Meglio, S.; Deschildre, C.; Loyau, S.; Olivot, J.M.; Blanc, R.; Piotin, M.; et al. Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis. Neurology 2019, 93, e1686–e1698. [Google Scholar] [CrossRef]
  51. Park, H.; Kim, J.; Ha, J.; Hwang, I.G.; Song, T.J.; Yoo, J.; Ahn, S.H.; Kim, K.; Kim, B.M.; Kim, D.J.; et al. Histological features of intracranial thrombi in stroke patients with cancer. Ann. Neurol. 2019, 86, 143–149. [Google Scholar] [CrossRef]
  52. Goebel, J.; Gaida, B.J.; Wanke, I.; Kleinschnitz, C.; Koehrmann, M.; Forsting, M.; Moenninghoff, C.; Radbruch, A.; Junker, A. Is Histologic Thrombus Composition in Acute Stroke Linked to Stroke Etiology or to Interventional Parameters? AJNR Am. J. Neuroradiol. 2020, 41, 650–657. [Google Scholar] [CrossRef]
  53. Pena-Martinez, C.; Duran-Laforet, V.; Garcia-Culebras, A.; Ostos, F.; Hernandez-Jimenez, M.; Bravo-Ferrer, I.; Perez-Ruiz, A.; Ballenilla, F.; Diaz-Guzman, J.; Pradillo, J.M.; et al. Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance. Stroke 2019, 50, 3228–3237. [Google Scholar] [CrossRef] [PubMed]
  54. Fu, C.H.; Chen, C.H.; Lin, Y.H.; Lee, C.W.; Tsai, L.K.; Tang, S.C.; Shun, C.T.; Jeng, J.S. Fibrin and Platelet-Rich Composition in Retrieved Thrombi Hallmarks Stroke with Active Cancer. Stroke 2020, 51, 3723–3727. [Google Scholar] [CrossRef] [PubMed]
  55. Fitzgerald, S.T.; Wang, S.; Dai, D.; Douglas, A.; Kadirvel, R.; Gounis, M.J.; Chueh, J.; Puri, A.S.; Layton, K.F.; Thacker, I.C.; et al. Platelet-rich clots as identified by Martius Scarlet Blue staining are isodense on NCCT. J. NeuroInterv. Surg. 2019, 11, 1145–1149. [Google Scholar] [CrossRef]
  56. Mereuta, O.M.; Fitzgerald, S.; Christensen, T.A.; Jaspersen, A.L.; Dai, D.; Abbasi, M.; Puttappa, T.; Kadirvel, R.; Kallmes, D.F.; Doyle, K.M.; et al. High-resolution scanning electron microscopy for the analysis of three-dimensional ultrastructure of clots in acute ischemic stroke. J. NeuroInterv. Surg. 2021, 13, 906–911. [Google Scholar] [CrossRef] [PubMed]
  57. Nouh, A.; Mehta, T.; Hussain, M.; Song, X.; Ollenschleger, M. Clot composition of embolic strokes of undetermined source: A feasibility study. BMC Neurol. 2020, 20, 383. [Google Scholar] [CrossRef]
  58. Novotny, J.; Oberdieck, P.; Titova, A.; Pelisek, J.; Chandraratne, S.; Nicol, P.; Hapfelmeier, A.; Joner, M.; Maegdefessel, L.; Poppert, H.; et al. Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction. Neurology 2020, 94, e2346–e2360. [Google Scholar] [CrossRef]
  59. Sporns, P.B.; Hanning, U.; Schwindt, W.; Velasco, A.; Buerke, B.; Cnyrim, C.; Minnerup, J.; Heindel, W.; Jeibmann, A.; Niederstadt, T. Ischemic Stroke: Histological Thrombus Composition and Pre-Interventional CT Attenuation Are Associated with Intervention Time and Rate of Secondary Embolism. Cerebrovasc. Dis. 2017, 44, 344–350. [Google Scholar] [CrossRef]
  60. Deng, J.; Zhao, F.; Zhang, Y.; Zhou, Y.; Xu, X.; Zhang, X.; Zhao, Y. Neutrophil extracellular traps increased by hyperglycemia exacerbate ischemic brain damage. Neurosci. Lett. 2020, 738, 135383. [Google Scholar] [CrossRef]
  61. Prochazka, V.; Jonszta, T.; Czerny, D.; Krajca, J.; Roubec, M.; Macak, J.; Kovar, P.; Kovarova, P.; Pulcer, M.; Zoubkova, R.; et al. The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke. Med. Sci. Monit. 2018, 24, 3929–3945. [Google Scholar] [CrossRef]
  62. Genchi, A.; Schwarz, G.; Semerano, A.; Callea, M.; Sanvito, F.; Simionato, F.; Panni, P.; Scomazzoni, F.; Doglioni, C.; Comi, G.; et al. Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. J. Neurol. Sci. 2020, 408, 116573. [Google Scholar] [CrossRef]
  63. Schuhmann, M.K.; Gunreben, I.; Kleinschnitz, C.; Kraft, P. Immunohistochemical Analysis of Cerebral Thrombi Retrieved by Mechanical Thrombectomy from Patients with Acute Ischemic Stroke. Int. J. Mol. Sci. 2016, 17, 298. [Google Scholar] [CrossRef]
  64. Essig, F.; Kollikowski, A.M.; Pham, M.; Solymosi, L.; Stoll, G.; Haeusler, K.G.; Kraft, P.; Schuhmann, M.K. Immunohistological Analysis of Neutrophils and Neutrophil Extracellular Traps in Human Thrombemboli Causing Acute Ischemic Stroke. Int. J. Mol. Sci. 2020, 21, 7387. [Google Scholar] [CrossRef] [PubMed]
  65. Chen, S.H.; Scott, X.O.; Ferrer Marcelo, Y.; Almeida, V.W.; Blackwelder, P.L.; Yavagal, D.R.; Peterson, E.C.; Starke, R.M.; Dietrich, W.D.; Keane, R.W.; et al. Netosis and Inflammasomes in Large Vessel Occlusion Thrombi. Front. Pharmacol. 2020, 11, 607287. [Google Scholar] [CrossRef] [PubMed]
  66. Dargazanli, C.; Rigau, V.; Eker, O.; Riquelme Bareiro, C.; Machi, P.; Gascou, G.; Arquizan, C.; Ayrignac, X.; Mourand, I.; Corlobé, A.; et al. High CD3+ Cells in Intracranial Thrombi Represent a Biomarker of Atherothrombotic Stroke. PLoS ONE 2016, 11, e0154945. [Google Scholar] [CrossRef] [PubMed]
  67. Douglas, A.; Fitzgerald, S.; Mereuta, O.M.; Rossi, R.; O’Leary, S.; Pandit, A.; McCarthy, R.; Gilvarry, M.; Holmegaard, L.; Abrahamsson, M.; et al. Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes. J. NeuroInterv. Surg. 2020, 12, 557–562. [Google Scholar] [CrossRef]
  68. Singh, P.; Doostkam, S.; Reinhard, M.; Ivanovas, V.; Taschner, C.A. Immunohistochemical analysis of thrombi retrieved during treatment of acute ischemic stroke: Does stent-retriever cause intimal damage? Stroke 2013, 44, 1720–1722. [Google Scholar] [CrossRef]
  69. Shin, J.W.; Jeong, H.S.; Kwon, H.-J.; Song, K.S.; Kim, J. High red blood cell composition in clots is associated with successful recanalization during intra-arterial thrombectomy. PLoS ONE 2018, 13, e0197492. [Google Scholar] [CrossRef]
  70. Woock, M.; Rossi, R.; Jabrah, D.; Douglas, A.; Redfors, P.; Nordanstig, A.; Tatlisumak, T.; Ceder, E.; Dunker, D.; Carlqvist, J.; et al. Clot signature in patients with large vessel occlusion stroke and concomitant active cancer. Eur. J. Neurol. 2025, 32, e70037. [Google Scholar] [CrossRef]
  71. Rojas-Bartolomé, L.; Payá, M.; Barbella-Aponte, R.; Restrepo Carvajal, L.; García-García, J.; Ayo-Martín, O.; Molina-Nuevo, J.D.; Serrano-Heras, G.; Juliá-Molla, E.; Pedrosa-Jiménez, M.J.; et al. Histopathological composition of thrombus material in a large cohort of patients with acute ischemic stroke: A study of atypical clots. Front. Neurol. 2025, 16, 1563371. [Google Scholar] [CrossRef]
  72. Juega, J.; Pagola, J.; Palacio, C.; Camacho, J.; Cardona, P.; Quesada, H.; Dorado, L.; Hernandez, M.; De la Torre, C.; Muchada, M.; et al. Abstract WMP70: Etiology of Stroke Based on Early Analysis of Clot Cytometry Obtained Through First Pass Technique for Mechanical Thrombectomy. Stroke 2019, 50, AWMP70. [Google Scholar] [CrossRef]
  73. Pagola, J.; Juega, J.; Dorado, L.; Hernandez-Perez, M.; Lazaro, C.; Garcia-Tornel, A.; Olive, M.; Requena, M.; Rubiera, M.; Muchada, M.; et al. Platelet Analysis in the Thrombus Plus Serum BNP for Detecting Clot-Related Atrial Fibrillation. Results from the ITACAT Multicentric Registry. Transl. Stroke Res. 2023, 16, 368–377. [Google Scholar] [CrossRef]
  74. Jabrah, D.; Rossi, R.; Molina, S.; Douglas, A.; Pandit, A.; McCarthy, R.; Gilvarry, M.; Ceder, E.; Fitzgerald, S.; Dunker, D.; et al. White blood cell subtypes and neutrophil extracellular traps content as biomarkers for stroke etiology in acute ischemic stroke clots retrieved by mechanical thrombectomy. Thromb. Res. 2024, 234, 1–8. [Google Scholar] [CrossRef]
  75. Huang, J.; Choudhri, T.F.; Winfree, C.J.; McTaggart, R.A.; Kiss, S.; Mocco, J.; Kim, L.J.; Protopsaltis, T.S.; Zhang, Y.; Pinsky, D.J.; et al. Postischemic Cerebrovascular E-Selectin Expression Mediates Tissue Injury in Murine Stroke. Stroke 2000, 31, 3047–3053. [Google Scholar] [CrossRef]
  76. Merten, M.; Thiagarajan, P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000, 102, 1931–1936. [Google Scholar] [CrossRef]
  77. Herbig, B.A.; Diamond, S.L. Thrombi produced in stagnation point flows have a core-shell structure. Cell. Mol. Bioeng. 2017, 10, 515–521. [Google Scholar] [CrossRef]
  78. Kadri, O.E.; Surblyte, M.; Chandran, V.D.; Voronov, R.S. Is the endothelial cell responsible for the thrombus core and shell architecture? Med. Hypotheses 2019, 129, 109244. [Google Scholar] [CrossRef] [PubMed]
  79. Zhao, Z.; Pan, Z.; Zhang, S.; Ma, G.; Zhang, W.; Song, J.; Wang, Y.; Kong, L.; Du, G. Neutrophil extracellular traps: A novel target for the treatment of stroke. Pharmacol. Ther. 2023, 241, 108328. [Google Scholar] [CrossRef]
  80. Massberg, S.; Grahl, L.; von Bruehl, M.-L.; Manukyan, D.; Pfeiler, S.; Goosmann, C.; Brinkmann, V.; Lorenz, M.; Bidzhekov, K.; Khandagale, A.B.; et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 2010, 16, 887–896. [Google Scholar] [CrossRef] [PubMed]
  81. Fuchs, T.A.; Brill, A.; Duerschmied, D.; Schatzberg, D.; Monestier, M.; Myers, D.D.; Wrobleski, S.K.; Wakefield, T.W.; Hartwig, J.H.; Wagner, D.D. Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. USA 2010, 107, 15880–15885. [Google Scholar] [CrossRef]
  82. Kimball, A.S.; Obi, A.T.; Diaz, J.A.; Henke, P.K. The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis. Front. Immunol. 2016, 7, 236. [Google Scholar] [CrossRef]
  83. Li, X.; Ma, Y.; Wang, D. The role of P-selectin/PSGL-1 in regulating NETs as a novel mechanism in cerebral ischemic injury. Front. Neurol. 2024, 15, 1442613. [Google Scholar] [CrossRef]
  84. He, L.; Liu, R.; Yue, H.; Zhang, X.; Pan, X.; Sun, Y.; Shi, J.; Zhu, G.; Qin, C.; Guo, Y. Interaction between neutrophil extracellular traps and cardiomyocytes contributes to atrial fibrillation progression. Signal Transduct. Target. Ther. 2023, 8, 279. [Google Scholar] [CrossRef] [PubMed]
  85. Xiang, J.; Cao, J.; Wang, X.; Shao, S.; Huang, J.; Zhang, L.; Tang, B. Neutrophil extracellular traps and neutrophil extracellular traps-related genes are involved in new-onset atrial fibrillation in LPS-induced sepsis. Int. Immunopharmacol. 2024, 138, 112550. [Google Scholar] [CrossRef] [PubMed]
  86. Cao, J.; Roth, S.; Zhang, S.; Kopczak, A.; Mami, S.; Asare, Y.; Georgakis, M.K.; Messerer, D.; Horn, A.; Shemer, R.; et al. DNA-sensing inflammasomes cause recurrent atherosclerotic stroke. Nature 2024, 633, 433–441. [Google Scholar] [CrossRef]
  87. Mengozzi, L.; Barison, I.; Malý, M.; Lorenzoni, G.; Fedrigo, M.; Castellani, C.; Gregori, D.; Malý, P.; Matěj, R.; Toušek, P.; et al. Neutrophil Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies. Stroke 2024, 55, 963–971. [Google Scholar] [CrossRef] [PubMed]
  88. Costamagna, G.; Bonato, S.; Corti, S.; Meneri, M. Advancing Stroke Research on Cerebral Thrombi with Omic Technologies. Int. J. Mol. Sci. 2023, 24, 3419. [Google Scholar] [CrossRef]
  89. Meissner, F.; Geddes-McAlister, J.; Mann, M.; Bantscheff, M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat. Rev. Drug Discov. 2022, 21, 637–654. [Google Scholar] [CrossRef]
  90. Letunica, N.; Van Den Helm, S.; McCafferty, C.; Swaney, E.; Cai, T.; Attard, C.; Karlaftis, V.; Monagle, P.; Ignjatovic, V. Proteomics in Thrombosis and Hemostasis. Thromb. Haemost. 2022, 122, 1076–1084. [Google Scholar] [CrossRef]
  91. Doche, E.; Sulowski, C.; Guigonis, J.-M.; Graslin, F.; Casolla, B.; Hak, J.-F.; Carle, X.; Brunel, H.; Lindenthal, S.; Martin, J.-C.; et al. How Clot Composition Influences Fibrinolysis in the Acute Phase of Stroke: A Proteomic Study of Cerebral Thrombi. Stroke 2024, 55, 1818–1829. [Google Scholar] [CrossRef]
  92. Dargazanli, C.; Zub, E.; Deverdun, J.; Decourcelle, M.; de Bock, F.; Labreuche, J.; Lefèvre, P.-H.; Gascou, G.; Derraz, I.; Riquelme Bareiro, C.; et al. Machine Learning Analysis of the Cerebrovascular Thrombi Proteome in Human Ischemic Stroke: An Exploratory Study. Front. Neurol. 2020, 11, 575376. [Google Scholar] [CrossRef]
  93. Rossi, R.; Mereuta, O.M.; Barbachan e Silva, M.; Molina Gil, S.; Douglas, A.; Pandit, A.; Gilvarry, M.; McCarthy, R.; O’Connell, S.; Tierney, C.; et al. Potential Biomarkers of Acute Ischemic Stroke Etiology Revealed by Mass Spectrometry-Based Proteomic Characterization of Formalin-Fixed Paraffin-Embedded Blood Clots. Front. Neurol. 2022, 13, 854846. [Google Scholar] [CrossRef]
  94. Kim, T.J.; Jung, J.W.; Kim, Y.-J.; Yoon, B.-W.; Han, D.; Ko, S.-B. Proteomic Analyses of Clots Identify Stroke Etiologies in Patients Undergoing Endovascular Therapy. CNS Neurosci. Ther. 2025, 31, e70340. [Google Scholar] [CrossRef]
  95. Arul, S.; Ghozy, S.; Mereuta, O.M.; Senol, Y.C.; Orscelik, A.; Kobeissi, H.; Gupta, R.; Brinjikji, W.; Kallmes, D.F.; Kadirvel, R. Metabolite signature in acute ischemic stroke thrombi: A systematic review. J. Thromb. Thrombolysis 2023, 56, 594–602. [Google Scholar] [CrossRef]
  96. Martha, S.R.; Levy, S.H.; Federico, E.; Levitt, M.R.; Walker, M. Machine Learning Analysis of the Cerebrovascular Thrombi Lipidome in Acute Ischemic Stroke. J. Neurosci. Nurs. 2023, 55, 10–17. [Google Scholar] [CrossRef] [PubMed]
  97. Li, W.; Bai, X.; Hao, J.; Xu, X.; Lin, F.; Jiang, Q.; Ding, C.; Dai, G.; Peng, F.; Zhang, M.; et al. Thrombosis origin identification of cardioembolism and large artery atherosclerosis by distinct metabolites. J. NeuroInterv. Surg. 2023, 15, 701–707. [Google Scholar] [CrossRef] [PubMed]
  98. Osakada, Y.; Yamashita, T.; Morihara, R.; Matsumoto, N.; Sasaki, R.; Tadokoro, K.; Nomura, E.; Kawahara, Y.; Omote, Y.; Hishikawa, N.; et al. 4-Hydroxyl-2-Nonenal Localized Expression Pattern in Retrieved Clots is Associated with Large Artery Atherosclerosis in Stroke Patients. J. Stroke Cerebrovasc. Dis. 2021, 30, 105583. [Google Scholar] [CrossRef]
  99. Suissa, L.; Guigonis, J.-M.; Graslin, F.; Robinet-Borgomano, E.; Chau, Y.; Sedat, J.; Lindenthal, S.; Pourcher, T. Combined Omic Analyzes of Cerebral Thrombi: A New Molecular Approach to Identify Cardioembolic Stroke Origin. Stroke 2021, 52, 2892–2901. [Google Scholar] [CrossRef]
  100. Abbasi, M.; Fitzgerald, S.; Ayers-Ringler, J.; Espina, V.; Mueller, C.; Rucker, S.; Kadirvel, R.; Kallmes, D.; Brinjikji, W. Proteomic Analysis of Cardioembolic and Large Artery Atherosclerotic Clots Using Reverse Phase Protein Array Technology Reveals Key Cellular Interactions Within Clot Microenvironments. Cureus 2021, 13, e13499. [Google Scholar] [CrossRef] [PubMed]
  101. Lopez-Pedrera, C.; Oteros, R.; Ibáñez-Costa, A.; Luque-Tévar, M.; Muñoz-Barrera, L.; Barbarroja, N.; Chicano-Gálvez, E.; Marta-Enguita, J.; Orbe, J.; Velasco, F.; et al. The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its etiology, severity, and prognosis. J. Thromb. Haemost. 2023, 21, 2894–2907. [Google Scholar] [CrossRef]
  102. Malik, R.; Chauhan, G.; Traylor, M.; Sargurupremraj, M.; Okada, Y.; Mishra, A.; Rutten-Jacobs, L.; Giese, A.-K.; van der Laan, S.W.; Gretarsdottir, S.; et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat. Genet. 2018, 50, 524–537. [Google Scholar] [CrossRef]
  103. Traylor, M.; Farrall, M.; Holliday, E.G.; Sudlow, C.; Hopewell, J.C.; Cheng, Y.-C.; Fornage, M.; Ikram, M.A.; Malik, R.; Bevan, S.; et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): A meta-analysis of genome-wide association studies. Lancet Neurol. 2012, 11, 951–962. [Google Scholar] [CrossRef]
  104. Jagodic, A.; Zivalj, D.; Krsek, A.; Baticic, L. Genetic Architecture of Ischemic Stroke: Insights from Genome-Wide Association Studies and Beyond. J. Cardiovasc. Dev. Dis. 2025, 12, 281. [Google Scholar] [CrossRef] [PubMed]
  105. Baek, B.H.; Kim, H.S.; Yoon, W.; Lee, Y.Y.; Baek, J.M.; Kim, E.H.; Kim, S.K. Inflammatory mediator expression within retrieved clots in acute ischemic stroke. Ann. Clin. Transl. Neurol. 2018, 5, 273–279. [Google Scholar] [CrossRef] [PubMed]
  106. Kukurba, K.R.; Montgomery, S.B. RNA Sequencing and Analysis. Cold Spring Harb. Protoc. 2015, 2015, 951–969. [Google Scholar] [CrossRef] [PubMed]
  107. Tutino, V.M.; Fricano, S.; Chien, A.; Patel, T.R.; Monteiro, A.; Rai, H.H.; Dmytriw, A.A.; Chaves, L.D.; Waqas, M.; Levy, E.I.; et al. Gene expression profiles of ischemic stroke clots retrieved by mechanical thrombectomy are associated with disease etiology. J. NeuroInterv. Surg. 2023, 15, e33–e40. [Google Scholar] [CrossRef]
  108. Renedo, D.; Barak, T.; DeLong, J.; Acosta, J.N.; Sujijantarat, N.; Koo, A.; Antonios, J.; Rivier, C.; Clocchiatti-Tuozzo, S.; Huo, S.; et al. Characterizing Stroke Clots Using Single-Cell Sequencing. medRxiv 2025, preprint. [Google Scholar] [CrossRef]
  109. Santo, B.A.; Poppenberg, K.E.; Ciecierska, S.-S.; Lim, J.; Baig, A.A.; Jaikumar, V.; Raygor, K.P.; Patel, T.R.; Shah, M.; Levy, E.I.; et al. Decoding Molecular Mechanisms Underlying Outcomes After Ischemic Stroke Thrombectomy by RNA Sequencing of Retrieved Clots. Mol. Diagn. Ther. 2024, 28, 469–477. [Google Scholar] [CrossRef]
  110. Santo, B.A.; Poppenberg, K.E.; Ciecierska, S.-S.K.; Baig, A.A.; Raygor, K.P.; Patel, T.R.; Shah, M.; Levy, E.I.; Siddiqui, A.H.; Tutino, V.M. Hybrid Clot Histomic–Transcriptomic Models Predict Functional Outcome After Mechanical Thrombectomy in Acute Ischemic Stroke. Neurosurgery 2024, 95, 1285–1296. [Google Scholar] [CrossRef]
  111. Stanton, K.; Philippou, H.; Ariëns, R.A.S. Ischaemic Stroke, Thromboembolism and Clot Structure. Neuroscience 2024, 550, 3–10. [Google Scholar] [CrossRef] [PubMed]
  112. LaGrange, D.D.; Reymond, P.; Brina, O.; Zboray, R.; Neels, A.; Wanke, I.; Lövblad, K.-O. Spatial heterogeneity of occlusive thrombus in acute ischemic stroke: A systematic review. J. Neuroradiol. 2023, 50, 352–360. [Google Scholar] [CrossRef] [PubMed]
  113. Brinjikji, W.; Mereuta, O.M.; Dai, D.; Kallmes, D.F.; Savastano, L.; Liu, Y.; Nimjee, S.M.; Nogueira, R.G.; Abbasi, M.; Kadirvel, R. Mechanisms of fibrinolysis resistance and potential targets for thrombolysis in acute ischaemic stroke: Lessons from retrieved stroke emboli. Stroke Vasc. Neurol. 2021, 6, 658–667. [Google Scholar] [CrossRef] [PubMed]
  114. Denorme, F.; Langhauser, F.; Desender, L.; Vandenbulcke, A.; Rottensteiner, H.; Plaimauer, B.; François, O.; Andersson, T.; Deckmyn, H.; Scheiflinger, F.; et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood 2016, 127, 2337–2345. [Google Scholar] [CrossRef]
  115. Niesten, J.M.; van der Schaaf, I.C.; van der Graaf, Y.; Kappelle, L.J.; Biessels, G.J.; Horsch, A.D.; Dankbaar, J.W.; Luitse, M.J.; van Seeters, T.; Smit, E.J.; et al. Predictive value of thrombus attenuation on thin-slice non-contrast CT for persistent occlusion after intravenous thrombolysis. Cerebrovasc. Dis. 2014, 37, 116–122. [Google Scholar] [CrossRef]
  116. Puig, J.; Pedraza, S.; Demchuk, A.; Daunis, I.E.J.; Termes, H.; Blasco, G.; Soria, G.; Boada, I.; Remollo, S.; Baños, J.; et al. Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator. AJNR Am. J. Neuroradiol. 2012, 33, 90–96. [Google Scholar] [CrossRef]
  117. Sporns, P.B.; Jeibmann, A.; Minnerup, J.; Broocks, G.; Nawabi, J.; Schön, G.; Fiehler, J.; Wildgruber, M.; Heindel, W.; Kemmling, A.; et al. Histological Clot Composition Is Associated with Preinterventional Clot Migration in Acute Stroke Patients. Stroke 2019, 50, 2065–2071. [Google Scholar] [CrossRef]
  118. Fitzgerald, S.; Mereuta, O.M.; Doyle, K.M.; Dai, D.; Kadirvel, R.; Kallmes, D.F.; Brinjikji, W. Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome. J. Neurosurg. Sci. 2019, 63, 292–300. [Google Scholar] [CrossRef]
  119. Liu, Y.; Brinjikji, W.; Abbasi, M.; Dai, D.; Arturo Larco, J.L.; Madhani, S.I.; Shahid, A.H.; Mereuta, O.M.; Nogueira, R.G.; Kvamme, P.; et al. Quantification of clot spatial heterogeneity and its impact on thrombectomy. J. NeuroInterv. Surg. 2022, 14, 1248–1252. [Google Scholar] [CrossRef]
  120. Nogueira, R.G.; Pinheiro, A.; Brinjikji, W.; Abbasi, M.; Al-Bayati, A.R.; Mohammaden, M.H.; Viana, L.S.; Ferreira, F.; Abdelhamid, H.; Bhatt, N.R.; et al. Clot composition and recanalization outcomes in mechanical thrombectomy. J. NeuroInterv. Surg. 2024, 16, 466–470. [Google Scholar] [CrossRef]
  121. Uchida, Y.; Kan, H.; Kano, Y.; Onda, K.; Sakurai, K.; Takada, K.; Ueki, Y.; Matsukawa, N.; Hillis, A.E.; Oishi, K. Longitudinal Changes in Iron and Myelination Within Ischemic Lesions Associate with Neurological Outcomes: A Pilot Study. Stroke 2024, 55, 1041–1050. [Google Scholar] [CrossRef] [PubMed]
  122. Baysoy, A.; Bai, Z.; Satija, R.; Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 2023, 24, 695–713. [Google Scholar] [CrossRef] [PubMed]
Jcm 14 06203 g001
Figure 1. A simplified schematic showing pathophysiological processes leading to atheroembolism and cardioembolism, the two primary causes of large-vessel occlusion (LVO). Created in BioRender. Sujijantarat, N. (2025) https://BioRender.com/tb9f0wn (accessed on 9 August 2025).
Figure 1. A simplified schematic showing pathophysiological processes leading to atheroembolism and cardioembolism, the two primary causes of large-vessel occlusion (LVO). Created in BioRender. Sujijantarat, N. (2025) https://BioRender.com/tb9f0wn (accessed on 9 August 2025).
Jcm 14 06203 g001
Jcm 14 06203 g002
Figure 2. A simplified schematic summarizing the published relationships between clot composition and stroke etiology to date. Where indicated, different components have been found to be more abundant in clots stemming from atheroembolic or cardioembolic etiologies, although significant heterogeneity exists. Proteomic and transcriptomic studies have shown that the associated pathways are distinct between stroke etiologies, although further work is needed to consistently define and understand these differences, their implications, and clinical utility. Created in BioRender. Sujijantarat, N. (2025) https://BioRender.com/rjmuicv (accessed on 9 August 2025).
Figure 2. A simplified schematic summarizing the published relationships between clot composition and stroke etiology to date. Where indicated, different components have been found to be more abundant in clots stemming from atheroembolic or cardioembolic etiologies, although significant heterogeneity exists. Proteomic and transcriptomic studies have shown that the associated pathways are distinct between stroke etiologies, although further work is needed to consistently define and understand these differences, their implications, and clinical utility. Created in BioRender. Sujijantarat, N. (2025) https://BioRender.com/rjmuicv (accessed on 9 August 2025).
Jcm 14 06203 g002
Table 1. Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification of subtypes of acute ischemic stroke [17].
Table 1. Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification of subtypes of acute ischemic stroke [17].
1 Large-artery atherosclerosis (embolus/thrombosis)
2 Cardioembolism (high-risk/medium-risk)
3 Small-vessel occlusion (lacune)
4 Stroke of other determined etiology
5 Stroke of undetermined etiology (“cryptogenic stroke”)
a. Two or more causes identified
b. Negative evaluation
c. Incomplete evaluation
Table 2. Common staining techniques for detection of macrocellular components and white blood cell subpopulations of the clot.
Table 2. Common staining techniques for detection of macrocellular components and white blood cell subpopulations of the clot.
ComponentStaining Technique
Red blood cellsH&E staining [48], MSB (selective quantification) [49], IHC CD235a antigen [50,51]
FibrinH&E staining [48], MSB (selective quantification) [49], Picro-Mallory (can also detect fibrin maturity in thrombi) [21], Ladewig trichrome [52]
PlateletsMSB [49], CD41 [53], CD42b [38,54,55,56], CD61 [57]
White blood cellsH&E staining [48], IHC CD45 antigen [58,59], neutrophil elastase [58], neutrophil myeloperoxidase [51]
   MonocytesLy6G [60], CD14 [58], CD15 [61], CD68 [44,62,63]
   GranulocytesLy6G [60]
   NeutrophilsLy6G [60], CD15 [61], CD66b [47,64]
NET-associated: citrullinated histones, caspase-1, and apoptosis-associated speck-like protein [65], granular neutrophil proteins (MPO), extracellular DNA [47]
   EosinophilCD15 [61]
   T-lymphocyteCD3 [66], CD4 [63]
  B-lymphocyteCD20 [44]
Coagulation proteinsantibodies against vWF [50,56,61,63,67]
  tPAplasminogen activator inhibitor-1 [50], protease nexin-1 [50]
  Elastic collagen fibersElastica van Gieson [52,68]
  Hemosiderin/ironPrussian blue [52]
  CalcificationsVon Kossa [52,68]
  CollagenMasson’s trichrome [21]
H&E, hematoxylin and eosin; IHC, immunohistochemical staining; MPO, myeloperoxidase; MSB, Martius Scarlet Blue; NET, neutrophil extracellular trap; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
Table 3. Summary of major WBC subcomposition differences comparing LAA and CE clots.
Table 3. Summary of major WBC subcomposition differences comparing LAA and CE clots.
WBC TypeLAA ClotCE ClotReferences
Innate Immune Cells↓ (less enriched)↑ (more enriched)[44,52,58,64,74]
CD68+ (Macrophages)
Jcm 14 06203 i001		↓↑[44,52]
NE+ MPO+ Neutrophils
Jcm 14 06203 i002		↓↑[58,64,74]
Adaptive Immune Cells↑↓[66,72,73,74]
CD3+ (lymphocytes)
Jcm 14 06203 i003		↑↓[66,74]
CD4+ (Helper T cells)
Jcm 14 06203 i004		↑↓[72,73]
CE, cardioembolism; LAA, large-artery atherosclerosis; MPO, myeloperoxidase; NE, neutrophil elastase; WBC, white blood cell.
Table 5. Literature on stroke etiologies and clot transcriptomics.
Table 5. Literature on stroke etiologies and clot transcriptomics.
ReferenceSample SizeTechniqueFindings
Tutino, 2023 [107]38 (21 CE, 6 LAA, 5 other determined cause, 6 cryptogenic)Paired-end RNA-seq
-
Compared to LAA, genes upregulated in CE clots include those involved in immune responses and cellular localization.
-
Compared to CE, genes upregulated in LAA clots include those involved in reactive oxygen species and oxidase activity.
Cryptogenic cases do not cluster towards only one group.
Specific limitations:
Descriptive observational findings only. Does not include predictive modeling or external validation.
Validation cohort contained low RNA concentrations, and only 3 DEGs could be tested.
Renedo, 2025 [108]12 (6 CE, 4 LAA, 2 venous)scRNA-seq
-
Genes upregulated in CE clots: GZMH, GZMB, S100A4, FCGBP2, HLA-A, TIMP1, CLIC1, and IFITM2.
-
Genes upregulated in LAA clots: CD74, HLA-DRB1*01, HTRA1, C1Q, CD81, and CR1.
Specific limitations:
Small sample size. Descriptive observational findings only. Does not include predictive modeling or external validation.
CE, cardioembolic; DEG, differentially expressed genes, LAA, large-artery atherosclerosis; scRNA-seq, single-cell RNA sequencing.
Table 6. Summary of current evidence linking various clot subcomponents to stroke etiology.
Table 6. Summary of current evidence linking various clot subcomponents to stroke etiology.
Clot ComponentsLAA ClotCE Clot
RBCs↑ (more enriched)↓ (less enriched)
Platelets/Fibrin↓↑
Innate Immune Cells↓↑
Adaptive Immune Cells↑↓
Multiomic pathwaysMultiple unique associationsMultiple unique associations
CE, cardioembolism; LAA, large-artery atherosclerosis; RBCs, red blood cells.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kosyakovsky, J.; Rossitto, C.P.; Antonios, J.P.; Renedo, D.; Stapleton, C.J.; Sansing, L.H.; Navaratnam, D.S.; Giles, J.A.; Patel, A.B.; Matouk, C.C.; et al. Clot Composition and Ischemic Stroke Etiology: A Contemporary Narrative Review. J. Clin. Med. 2025, 14, 6203. https://doi.org/10.3390/jcm14176203

AMA Style

Kosyakovsky J, Rossitto CP, Antonios JP, Renedo D, Stapleton CJ, Sansing LH, Navaratnam DS, Giles JA, Patel AB, Matouk CC, et al. Clot Composition and Ischemic Stroke Etiology: A Contemporary Narrative Review. Journal of Clinical Medicine. 2025; 14(17):6203. https://doi.org/10.3390/jcm14176203

Chicago/Turabian Style

Kosyakovsky, Jacob, Christina P. Rossitto, Joseph P. Antonios, Daniela Renedo, Christopher J. Stapleton, Lauren H. Sansing, Dhasakumar S. Navaratnam, James A. Giles, Aman B. Patel, Charles C. Matouk, and et al. 2025. "Clot Composition and Ischemic Stroke Etiology: A Contemporary Narrative Review" Journal of Clinical Medicine 14, no. 17: 6203. https://doi.org/10.3390/jcm14176203

APA Style

Kosyakovsky, J., Rossitto, C. P., Antonios, J. P., Renedo, D., Stapleton, C. J., Sansing, L. H., Navaratnam, D. S., Giles, J. A., Patel, A. B., Matouk, C. C., & Sujijantarat, N. (2025). Clot Composition and Ischemic Stroke Etiology: A Contemporary Narrative Review. Journal of Clinical Medicine, 14(17), 6203. https://doi.org/10.3390/jcm14176203

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop